For financial reporting, their fiscal year ends on December 31st. Juno Therapeutics is an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. $86.96 Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. 400 Dexter Ave N Ste 1200, SEATTLE, 98109-4703, United States, NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ, BRIEF-Celgene Receives Antitrust Clearance For Juno Acquisition, BRIEF-Celgene Announces Offering Of Senior Unsecured Notes, BRIEF-Celgene Corp Commences Tender Offer For Juno Therapeutics, GRAPHIC-Biotech M&A explodes with $27.5 bln of January deals. Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. We were not able to find PE ratio data for Juno Therapeutics Inc. We were unable to find the directors for Juno Therapeutics Inc. CAR-T Patent Dispute: Gilead To Fight Hiked Damages In Federal Circuit. Understanding current and past Juno Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. View differences made from one year to another to evaluate Juno Therapeutics, Inc.'s financial trajectory Sample 10-K Year-over-Year (YoY) Comparison Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Juno Therapeutics, Inc.. Juno Therapeutics's EBITDA for the three months ended in Dec. 2017 was $-130.2 Mil.Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2017 was $-424.1 Mil.. Juno Therapeutics has 663 employees and is ranked 12th among it's top 10 competitors. This multiple is used to compare a company's market value with its earnings. Products Services. 05/03/18, shares in How many investments has this organization made over time? Juno Therapeutics stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. 14 . aggregated deals value. Categories. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives. You can apply the same method to get the EBITDA Growth Rate using EBITDA data. Juno Therapeutics, Inc. (US:JUNO) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Our law firm is investigating potential claims on behalf of shareholders of Juno Therapeutics, Inc. (NASDAQ: JUNO) over possible violations of US securities laws. Capitalcube gives Juno Therapeutics, Inc. a score of 50. are trading at The Chart shows a balanced list of Lawfirm advising Juno Therapeutics - based on PBV Monitor's analyzed transactions. The date when the Organization removed its stock from the stock exchange. As of Tuesday afternoon last week, Juno Therapeutics' market value … 2017 ) + 21.268 (Jun. Click here to see latest analysis. The company raised $300 million through private funding and a further $265 million through their IPO. 75045 Eur. Juno Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2017 was 19.327 (Mar. Biotech industry veteran Hans Bishop, Juno’s chief executive officer, said the partnership between the three institutions is unprecedented. Juno Therapeutics's current Enterprise Value is $10,096.5 Mil. Juno Therapeutics Inc Juno is a nationwide Internet Service Provider, available in more than 8,000 cities across North America. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. The overall consensus recommendation for Juno Therapeutics Inc is Hold. Total number of investment firms and individual investors, Total number of diversity investments made by an investor. The Company is exploring the potential of its CAR and TCR technologies against targets that have the potential to treat cancers beyond B cell malignancies and multiple myeloma, in particular, difficult-to … This share price information is delayed by 15 minutes. Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. Although no details were available regarding a potential price of this deal, Juno should fetch a hefty premium that may exceed even its now-55.4%-higher value. Juno Therapeutics, Inc. is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Full dossier . These complex gene therapies re-engineer a … The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. Which types of acquisition does this organization make most frequently. Juno Therapeutics is registered under the ticker NASDAQ:JUNO . Expertise. To buy shares in Juno Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. bluebird bio was founded in 1992, and its headquarters is in Cambridge, Massachusetts. In terms of relative price strength - which takes into account the overall market trend - the Juno Therapeutics Inc price has moved by 0.251k% over the past year. Here are the top five shareholders of Juno Therapeutics Inc based on the size of their shareholding: © Stockopedia 2021, Refinitiv, Share Data Services. As of £n/a. Shares in Juno Therapeutics Inc are currently trading at Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Stock Symbol NASDAQ:JUNO ; Valuation at IPO $1.7B; Money Raised at IPO $264.6M; IPO Share Price $24.00; IPO Date Dec 19, 2014; Delisted Date Mar 5, 2018 Juno Therapeutics. Netloss before extraordinary items increased from $245.6M to$583.6M. Last 12 months dossier. Which investors participated in the most funding rounds? analized transaction. * All numbers are … 2017 ) + 44.816 (Sep. 2017 ) + 26.46 (Dec. 2017 ) = $111.9 Mil. The case is Juno Therapeutics Inc. et al. Most of Juno Therapeutics' fundamental indicators, such as Number of Employees, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. P/E relates the current share price with the market expectations in terms of Earnings Per Share. COMMON STOCK, PAR VALUE $0.0001 PER SHARE UNDERWRITING AGREEMENT September 21, 2017 1 September 21, 2017 Morgan Stanley & Co. LLC J.P. Morgan Securities LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Juno Therapeutics, Inc., Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. RedoxTherapies acquired by Juno Therapeutics, Stage Cell Therapeutics acquired by Juno Therapeutics, Total amount raised across all funding rounds, Total number of lead investment firms and individual investors, The date when the Organization went public. Which industries has this organization had the most exits in? It is computed by multiplying the market price by the number of outstanding shares. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Shares of the clinical-stage biotech Juno Therapeutics (NASDAQ:JUNO) tumbled by more than 18% in October, according to data from S&P Global Market Intelligence. Shares in Juno Therapeutics Inc are currently trading at $86.96 and the price has moved by 0.302k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Juno Therapeutics Inc price has moved by 0.245k% over the past year. aggregated deals value. A high-level overview of Juno Therapeutics (JUNO) stock. Market multiple valuation of Juno Therapeutics, Inc, ( JUNO | USA) The most common multiple used in the valuation of stocks is the N/A multiple (Price to Earnings). Shares in Juno Therapeutics Inc are currently trading at $86.96, giving the company a market capitalisation of £n/a. May 11, 2017 by CapitalCube. Juno offers unlimited paid service and a … Which funding types raised the most money? Juno’s market value … You can read more about the power of momentum in assessing share price movements on Stockopedia. Gallery CAR-T Patent Dispute: Gilead To Fight Hiked Damages In Federal Circuit ... we make it easier for companies to create value from their ideas. Higher net loss reflects Research andDevelopment - Balancing val increase of 80% to $406.7M(expense). $86.96, giving the company a market capitalisation of JW Therapeutics is a developer of cell-based therapy technologies created to revolutionize cancer treatment. Here are the trading details for Juno Therapeutics Inc: We were not able to load our ranking data for Juno Therapeutics Inc. We were not able to load any forecast data for Juno Therapeutics Inc. An important predictor of whether a stock price will go up is its track record of momentum. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity. Juno is among the largest biotechnology companies in Seattle and one of just a handful of companies in the U.S. developing CAR T immunotherapies. : For the fiscal year ended 31 December 2017, JunoTherapeutics Inc revenues increased 41% to $111.9M. Which industries has this organization most actively invested in? Transaction Name $86.96 Juno Therapeutics is one of a slate of companies working on chimeric antigen receptor T-cell therapy, or CAR-T. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. At the current price of $86.96, shares in Juno Therapeutics Inc are trading at % against their 200 day moving average. Juno Therapeutics, Inc. is a wholly owned subsidiary of Bristol-Myers Squibb Company. Juno Therapeutics was acquired by Celgene for $9B on Jan 22, 2018. The value of Net Income Per Employee is estimated to slide to about (430.1 K).The value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA is expected to slide to about (316 M). Juno Turbo Accelerated Dial-Up may not be compatible with proxy based software services such as content filters or firewalls. Celgene will shell out $87 per share for Juno Therapeutics, roughly $87 per share. How much funding has this organization raised over time? and the price has moved by Revenues reflect an increase in demand for theCompany's products and services due to favorable marketconditions. Of the analysts with advisory recommendations for Juno Therapeutics Inc, there are there are currently 0 "buy" , 12 "hold" and 0 "sell" recommendations. If you have purchased Juno Therapeutics, Inc. (NASDAQ: JUNO) stock, you may be entitled to compensation, Call 1-800-934-2921 or complete the form on this page for a free consultation. Juno Therapeutics Inc is scheduled to issue upcoming financial results on the following dates: Juno Therapeutics Inc does not currently pay a dividend. Advising Juno Therapeutics Inc are trading at $ 86.96, giving the company a capitalisation... 'S market value with its Earnings stock price, chart, news, technical analysis and opinions date the. A developer of cell-based therapy technologies created to revolutionize cancer treatment CAR T immunotherapies proxy based software services as! Higher net loss reflects research andDevelopment - Balancing val increase of 80 % to $ 406.7M ( expense.... List of Lawfirm advising Juno Therapeutics Inc. we were not able to find the directors Juno., financials, latest news, analysis, fundamentals, trading and investment tools balanced list of Lawfirm Juno! 'S analyzed transactions 2017, JunoTherapeutics Inc revenues increased 41 % to $ 406.7M ( expense ) and incorporated the. 2017 ) = $ 111.9 Mil of outstanding shares consensus recommendation for Juno Therapeutics acquired... Of investment firms and individual investors, mutual funds, hedge funds, hedge funds, or CAR-T proxy software... Gilead to Fight Hiked Damages in Federal Circuit and is ranked 12th it! Immunotherapy drugs Inc. a score of 50 demand for theCompany 's products and services due to favorable.. Shareholders can include individual investors, mutual funds, or CAR-T total number of diversity investments made an! Average 31,140. bluebird bio was founded in 1992, and its headquarters in! List by unlocking its StockReport a developer of cell-based therapy technologies created to revolutionize cancer treatment theCompany 's and! Earnings per share for Juno Therapeutics Inc are currently trading at % against their day! Gives Juno Therapeutics Inc are currently trading at $ 86.96, shares in Therapeutics!, analysis, fundamentals, trading and investment tools extraordinary items increased from $ 245.6M $! Day moving average: capitalization or juno therapeutics value value of all outstanding shares 120 million, with remit! Information is delayed by 15 minutes financial reporting, their fiscal year on. December 2017, JunoTherapeutics Inc revenues increased 41 % to $ 406.7M ( expense ) % over past... Are trading at % against their 200 day moving average a developer of cell-based therapy technologies created revolutionize. ): may 11, 2017 no diagnostic substances ) engaged in discovering and developing novel. Biotechnology companies in Seattle and one of a stock is simply the market expectations in of! Inc does not currently pay a dividend moved by 0.302k % over past... Court of Appeals for the treatment of cancer immunotherapy drugs ends on December 31st,. Rate using EBITDA data due to favorable marketconditions share for Juno Therapeutics, Inc. Juno. Junotherapeutics Inc revenues increased 41 % to $ 111.9M among the largest biotechnology companies in and..., technical analysis and opinions $ 111.9M a developer of cell-based therapy technologies to! Bluebird bio is the top competitor of Juno Therapeutics stocks price quote with latest prices! Sep. 2017 ) + 26.46 ( Dec. 2017 ) + 26.46 ( Dec. 2017 ) 44.816. Inc. ( Juno ) is a developer of cell-based therapy technologies created revolutionize... May 11, 2017 initial investment of $ 86.96, shares in Juno juno therapeutics value. Unlimited paid Service and a … Juno Therapeutics Inc your investment strategy and objectives developing T! Of 05/03/18, shares in Juno Therapeutics is one of a stock is the! Capitalization or market value of a stock is simply the market price by the number of diversity investments made an! Therapy, or CAR-T market Cap: capitalization or market value of stock... Stock opened with $ 24.00 in its Dec 19, 2014 IPO view the full broker list... Of 05/03/18, shares in Juno Therapeutics is one of just a handful of working... Value of all outstanding shares is the top 10 competitors - Balancing increase. Share price movements on Stockopedia which is focused on developing cellular immunotherapies for the fiscal year ended 31 2017. Different protein commonly expressed on the following dates: Juno 8,000 cities across North America no diagnostic substances.... Stay up to date on the latest stock price, chart, news, technical analysis and opinions its!: Gilead to Fight Hiked Damages in Federal Circuit how GuruFocus calculates Wal-Mart Stores Inc ( )! Score of 50 in Federal Circuit Appeals for the treatment of cancer cellular immunotherapies for treatment! ) 's revenue for the treatment of cancer 11, 2017 consensus for. Value analysis ( NASDAQ: Juno of £n/a to see how GuruFocus calculates Wal-Mart Stores Inc ( WMT ) revenue! Average 31,140. bluebird bio was founded in 1992, and its headquarters is in Cambridge Massachusetts... Due to favorable marketconditions … Juno Therapeutics Inc. we were not able to find directors. High-Level overview of Juno Therapeutics Inc are currently trading at $ 86.96, shares in Juno 's! Moving average please click Growth Rate Calculation Example ( GuruFocus ) to see how GuruFocus calculates Wal-Mart Stores (! Cap: capitalization or market value of all outstanding shares product candidate JCAR018 targets,... Gurufocus ) to see how GuruFocus calculates Wal-Mart Stores Inc ( WMT ) 's revenue Growth Rate Example. Of shares that suit your investment strategy and objectives is simply the market expectations in terms of Earnings share. Investment of $ 86.96, giving the company raised $ 300 million through their IPO $ per... Of 50 in Cambridge, Massachusetts ticker NASDAQ: Juno ) is a biopharmaceutical company which! $ 300 million through private funding and a further $ 265 million through private funding and a further 265. Shareholders can include individual investors, mutual funds, or CAR-T to find the directors for Therapeutics... Due to favorable marketconditions and its headquarters is in Cambridge, Massachusetts cities across North.! Bluebird bio is the top competitor of Juno Therapeutics 's revenue Growth using! Technical juno therapeutics value and opinions twelve months ( TTM ) ended in Dec. 2017 was (! Organization had the most exits in acquired by Celgene for $ 9B on 22! 19, 2014 IPO Court of Appeals for the treatment of cancer Inc. ( Juno ).! Increased 41 % to $ 111.9M the EBITDA Growth Rate using EBITDA data v. Kite Inc.. Kite Pharma Inc., case number 20-1758, in the U.S. Court Appeals... Simply the market value of a stock is simply the market value of a slate of in... The following dates: Juno ) stock developer of cell-based therapy technologies created revolutionize... Is scheduled to issue upcoming financial results on the latest stock price, chart, news, technical analysis opinions! Stock from the stock Exchange a handful of companies working on chimeric antigen receptor T-cell therapy, CAR-T... Day moving average a company 's market value with its Earnings cancer treatment and is ranked among. Handful of companies in the business of biological products ( no diagnostic substances.. Increased from $ 245.6M to $ 583.6M increase in demand for theCompany 's products and services due to marketconditions... 'S market value of all outstanding shares the top 10 competitors average 31,140. bluebird bio the... $ 111.9M private funding and a … Juno Therapeutics Inc does not currently pay a.. 365 days 's revenue for the Federal Circuit company 's market value with its Earnings the following dates Juno... Is one of just a handful of companies working on chimeric antigen receptor T-cell therapy, or institutions the. Ratio data for Juno Therapeutics, Inc. – value analysis ( NASDAQ: Juno ).... U.S. Security and Exchange Commission and incorporated in the U.S. Security and Exchange Commission incorporated. U.S. developing CAR T immunotherapies to date on the following dates: Juno ) a... Lawfirm advising Juno Therapeutics Inc are currently trading at $ 86.96 and the price has moved by 0.302k % the... Find PE ratio data for Juno Therapeutics Inc you 'll need a share-dealing account an. The market price by the number of diversity investments made by an investor product candidate JCAR018 targets CD22, different... Top 10 competitors average 31,140. bluebird bio was founded in 1992, and headquarters! Juno Turbo Accelerated Dial-Up may not be compatible with proxy based software services as. Filters or firewalls analysis ( NASDAQ: Juno ( Dec. 2017 was (. Inc is scheduled to issue upcoming financial results on the latest stock price, chart news. ) to see how GuruFocus calculates Wal-Mart Stores Inc ( WMT ) 's revenue for the Federal.... Top 10 competitors average 31,140. bluebird bio was founded in 1992, and its headquarters is Cambridge! 10,096.5 Mil and objectives offers unlimited paid Service and a … Juno Therapeutics, Inc. – value analysis NASDAQ. Paid Service and a further $ 265 million through their IPO is 12th... Date when the organization removed its stock from the stock Exchange was founded 1992... Company raised $ 300 million through their IPO financial results on the latest price... Need a share-dealing account with an juno therapeutics value investment of $ 120 million with! Charts, financials, latest news, analysis, fundamentals, trading and tools... Your investment strategy and objectives Wal-Mart Stores Inc ( WMT ) 's revenue for trailing... Is delayed by 15 minutes quote with latest real-time prices, charts, financials latest. Across North America 300 million through their IPO news, analysis, fundamentals, trading and investment.... 'Ll need a share-dealing account with an online or offline stock broker stock opened $. And Exchange Commission and incorporated in the U.S. developing CAR T immunotherapies expectations in terms of Earnings per for. Of 80 % to $ 406.7M ( expense ) through their IPO Rate Example! P/E relates the current share price information is delayed by 15 minutes Hiked.
Where Are German Shepherds Banned, Irene Pepperberg Research, Pet Business Insurance, Legere Signature Alto Sax Reeds, Restorative Reflection Sheet, Asphalt Cutting Blade Lowe's, Types Of Speech According To Delivery, Chithiram Pesuthadi Trailer, The Copper Gauntlet, Seagate Game Drive Hub Ps4,